Diet and Physical Activity in Fabry Disease: A Narrative Review
Fabry disease (FD) is caused by mutations in the galactosidase alpha (GLA) gene which lead to the accumulation of globotriaosylceramide (Gb-3). Enzyme replacement therapy (ERT) and oral chaperone therapy are the current pharmacological treatments for this condition. However, in the literature, there...
Main Authors: | Giovanna Muscogiuri, Oriana De Marco, Tonia Di Lorenzo, Maria Amicone, Ivana Capuano, Eleonora Riccio, Guido Iaccarino, Antonio Bianco, Teodolinda Di Risi, Antonio Pisani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-04-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/16/7/1061 |
Similar Items
-
New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review
by: Eleonora Riccio, et al.
Published: (2023-01-01) -
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations
by: Jessica Gambardella, et al.
Published: (2024-01-01) -
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept
by: Teodolinda Di Risi, et al.
Published: (2022-10-01) -
Gastrointestinal Manifestations and Low-<i>FODMAP</i> Protocol in a Cohort of Fabry Disease Adult Patients
by: Giorgia Gugelmo, et al.
Published: (2023-01-01) -
Cisti Parapieliche. Un Elemento di Sospetto Per la Diagnosi di Malattia di Fabry
by: Livia Maria Sorrentino, et al.
Published: (2017-04-01)